KMT2A and leukemia: This compound exhibited potent WDR5 binding with a Ki value of 0.049 nM, potent MLL1 histone methyltransferase inhibition (IC50: 3.4 nM), and antiproliferative activity with GI50 values of 15,000, 470, and 480 nM against K562 leukemia, MV4-11, and MOLM-13 cell lines (the former cell line is p53 null, while the latter two MLL-fusion cell lines express wild-type p53).